What is Nabsys?
Nabsys is dedicated to revolutionizing the understanding of disease, increasing diagnostic yield, and improving patient outcomes. The company achieves this by enabling routine, accurate, and cost-effective analysis of genomic structural variation. Based in Providence, RI, Nabsys comprises a growing team of scientists, engineers, and professionals committed to pushing the boundaries of genomic analysis. Their work is critical in the rapidly evolving field of precision medicine and genetic diagnostics.
How much funding has Nabsys raised?
Nabsys has raised a total of $117.5M across 13 funding rounds:
Series C
$10M
Debt
$4.7M
Grant
$244K
Private Equity
$25.5M
Private Equity
$6M
Other Financing Round
$21M
Debt
$150K
Private Equity
$38M
Series C (2011): $10M, investors not publicly disclosed
Debt (2012): $4.7M, investors not publicly disclosed
Grant (2012): $244K supported by Internal Revenue Service
Private Equity (2014): $25.5M featuring Rose Ventures, Inc and Bay City Capital
Private Equity (2016): $6M backed by Jilin Zixin Pharmaceutical Industrial Co., Ltd
Other Financing Round (2019): $21M with participation from Hitachi High-Technologies Corporation
Debt (2020): $150K led by PPP
Private Equity (2022): $38M supported by Hitachi High-Tech Corporation
Key Investors in Nabsys
Rose Ventures, Inc
Rose Ventures Inc. is a venture capital firm specializing in early-stage life science companies, offering strategic advisory services and leveraging its network to foster growth. As of January 2026, it is part of Miles Pond Press, LLC.
Bay City Capital
Bay City Capital is a venture capital firm founded in 1997 that focuses on life sciences investments, having backed over 100 companies worldwide with $1.3 billion in capital commitments.
Jilin Zixin Pharmaceutical Industrial Co., Ltd
Jilin Zixin Pharmaceutical Industrial Co.,Ltd is a China-based company involved in the research, development, production, and sale of Chinese medicines and gene sequencers.
What's next for Nabsys?
The recent major strategic investment and the overall substantial capital raised by Nabsys indicate a strong market confidence in its technology and its potential to disrupt the genomic analysis sector. This capital infusion is likely to fuel further research and development, scale manufacturing capabilities, and expand market reach. Nabsys is positioned to become a key player in advancing genomic diagnostics, potentially leading to breakthroughs in disease detection and personalized treatment strategies. The company's trajectory suggests a focus on commercialization and broader adoption of its innovative solutions.
See full Nabsys company page
